Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01924455 · ClinicalTrials.gov registry record
HBV-HIV Coinfection Research Network
A clinical trial, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- 139
- Enrollment target
NCT01924455 is a clinical trial that has completed, run by Virginia Commonwealth University. The registered enrollment target is 139 participants.
The verdict
NCT01924455 has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- 139 participants
- Enrollment target
Study Summary
Despite effective ART that can suppress both HIV and HBV, HBV-related liver disease remains a significant co-morbidity in this population. Little is known about the histologic spectrum of liver disease, the significance of complete vs. incomplete HBV suppression, the utility of novel virologic and serum markers of disease severity, and the long-term renal and bone effects of TDF-based therapy. This proposal will address these important questions and impact the science and health of those coinfected with HBV-HIV.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 139 participants |
| Start Date | 2014-04 |
| Est. Completion | 2019-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01924455
The ClinicalTrials.gov registry entry for NCT01924455 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01924455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01924455 about?
NCT01924455 is a clinical study titled "HBV-HIV Coinfection Research Network". Despite effective ART that can suppress both HIV and HBV, HBV-related liver disease remains a significant co-morbidity in this population. Little is known about the histologic spectrum of liver disease, the significance of complete vs. incomplete HBV suppression, the utility of novel virologic and s...
What is the current status of trial NCT01924455?
This trial is currently completed. The enrollment target is 139 participants. The study started on 2014-04. Estimated completion is 2019-03-31.
Who is sponsoring clinical trial NCT01924455?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.